Jochen Schmitt
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
Schmitt, Jochen; Spuls, Phyllis I.; Thomas, Kim S.; Simpson, Eric; Furue, Masutaka; Deckert, Stefanie; Dohil, Magdalene; Apfelbacher, Christian; Singh, Jasvinder A.; Chalmers, Joanne; Williams, Hywel C.
Authors
Phyllis I. Spuls
Professor KIM THOMAS KIM.THOMAS@NOTTINGHAM.AC.UK
Professor of Applied Dermatology Research
Eric Simpson
Masutaka Furue
Stefanie Deckert
Magdalene Dohil
Christian Apfelbacher
Jasvinder A. Singh
Joanne Chalmers
HYWEL WILLIAMS HYWEL.WILLIAMS@NOTTINGHAM.AC.UK
Professor of Dermato-Epidemiology
Abstract
The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) initiative has already defined clinical signs, symptoms, quality of life, and long-term control of flares as core outcome domains for AE trials. This article deals with the standardization of measurement instruments to assess clinical signs of AE. To resolve the current lack of standardization of the assessment of clinical signs of AE, we followed a structured process of systematic reviews and international consensus sessions to identify 1 core outcome measurement instrument for assessment of clinical signs in all future AE trials. Systematic reviews indicated that from 16 different instruments identified to assess clinical signs of AE, only the Eczema Area and Severity Index (EASI) and the objective Scoring Atopic Dermatitis (SCORAD) index were identified as extensively validated. The EASI has adequate validity, responsiveness, internal consistency, and intraobserver reliability. The objective SCORAD index has adequate validity, responsiveness, and interobserver reliability but unclear intraobserver reliability to measure clinical signs of AE. In an international consensus study, patients, physicians, nurses, methodologists, and pharmaceutical industry representatives agreed that the EASI is the preferred core instrument to measure clinical signs in all future AE trials. All stakeholders involved in designing, reporting, and using clinical trials on AE are asked to comply with this consensus to enable better evidence-based decision making, clearer scientific communication, and improved patient care.
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 25, 2014 |
Publication Date | Oct 1, 2014 |
Deposit Date | Sep 17, 2018 |
Electronic ISSN | 1097-6825 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 134 |
Issue | 4 |
Pages | 800-807 |
DOI | https://doi.org/10.1016/j.jaci.2014.07.043 |
Keywords | Atopic dermatitis; clinical trials; eczema; Eczema Area and Severity Index; evidence-based medicine; outcomes research |
Public URL | https://nottingham-repository.worktribe.com/output/1105351 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0091674914010471 |
PMID | 25282560 |
Additional Information | eStaffProfile Description: , eStaffProfile Brief Description of Type: |
You might also like
Validation of treatment escalation as a definition of atopic eczema flares
(2015)
Journal Article
New treatments for atopic dermatitis
(2002)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search